OBJECTIVE: To investigate the prognostic impact of the individual component comorbidities of the hematopoietic cell transplant comorbidity index (HCT-CI) in patients with acute myeloid leukemia (AML) that underwent allogeneic hematopoietic cell transplant (HCT). METHOD: This single-center study retrospectively investigated the individual comorbidities of the HCT-CI on the outcome of 418 patients that underwent HCT for AML, in CR1 (n = 303, 72%) or CR2 (n = 115, 28%) at our center between 1999 and 2014. RESULTS: Median age at HCT was 50 years (range 18-71). Univariate analysis of the HCT-CI, grouped as score 0 (n = 109), 1-2 (n = 157) and ≥3 (n = 152), demonstrated significant influence on overall survival (OS) (P = .004) and non-relapse mortality (NRM) (P = .02). For individual comorbidities constituting the HCT-CI, variables with a P-value ≤ .2 on univariate analysis were included in the multivariable analysis. For OS, none of the comorbidities of the HCT-CI demonstrated independent prognostic relevance. However, for NRM, multivariable analysis demonstrated pretransplant diabetes (HR = 2.17, 95% CI = 1.31-3.60, P = .003) and cardiovascular comorbidity (HR = 1.78, 95% CI = 1.15-2.76, P = .01) to be independent predictors of NRM post-transplant. CONCLUSION: Among the comorbidities that compose the HCT-CI, diabetes and cardiovascular comorbidity independently predict NRM in patients undergoing allogeneic HCT for AML. This information should be taken into consideration regarding post-transplant monitoring and care.
OBJECTIVE: To investigate the prognostic impact of the individual component comorbidities of the hematopoietic cell transplant comorbidity index (HCT-CI) in patients with acute myeloid leukemia (AML) that underwent allogeneic hematopoietic cell transplant (HCT). METHOD: This single-center study retrospectively investigated the individual comorbidities of the HCT-CI on the outcome of 418 patients that underwent HCT for AML, in CR1 (n = 303, 72%) or CR2 (n = 115, 28%) at our center between 1999 and 2014. RESULTS: Median age at HCT was 50 years (range 18-71). Univariate analysis of the HCT-CI, grouped as score 0 (n = 109), 1-2 (n = 157) and ≥3 (n = 152), demonstrated significant influence on overall survival (OS) (P = .004) and non-relapse mortality (NRM) (P = .02). For individual comorbidities constituting the HCT-CI, variables with a P-value ≤ .2 on univariate analysis were included in the multivariable analysis. For OS, none of the comorbidities of the HCT-CI demonstrated independent prognostic relevance. However, for NRM, multivariable analysis demonstrated pretransplant diabetes (HR = 2.17, 95% CI = 1.31-3.60, P = .003) and cardiovascular comorbidity (HR = 1.78, 95% CI = 1.15-2.76, P = .01) to be independent predictors of NRM post-transplant. CONCLUSION: Among the comorbidities that compose the HCT-CI, diabetes and cardiovascular comorbidity independently predict NRM in patients undergoing allogeneic HCT for AML. This information should be taken into consideration regarding post-transplant monitoring and care.
Authors: María García-Fortes; Juan C Hernández-Boluda; Alberto Álvarez-Larrán; José M Raya; Anna Angona; Natalia Estrada; Laura Fox; Beatriz Cuevas; María C García-Hernández; María Teresa Gómez-Casares; Francisca Ferrer-Marín; Silvana Saavedra; Francisco Cervantes; Regina García-Delgado Journal: Cancers (Basel) Date: 2022-05-09 Impact factor: 6.575
Authors: Omer Jamy; Alice Chen; Kevin Battles; Liton Francisco; Donna Salzman; Susan Bal; Antonio Di Stasi; Luciano Costa; Ravi Bhatia; Smita Bhatia Journal: Bone Marrow Transplant Date: 2021-01-08 Impact factor: 5.174
Authors: Olaf Penack; Christophe Peczynski; Mohamad Mohty; Ibrahim Yakoub-Agha; Rafael de la Camara; Bertram Glass; Rafael F Duarte; Nicolaus Kröger; Hélène Schoemans; Christian Koenecke; Zinaida Peric; Grzegorz W Basak Journal: Bone Marrow Transplant Date: 2021-10-30 Impact factor: 5.483